| Number of trials n = 71 (%) | Secondary Endpoints absent from registry n = 36 (%) | P value | Secondary Endpoints absent from protocol n = 19 (%) | P value |
---|---|---|---|---|---|
Trial Initiation Period | |||||
 1994–2005 | 30 (42) | 15 (42) | 0.9191 | 8 (42) | 0.9878 |
 2006–2010 | 41 (58) | 21 (58) |  | 11 (58) |  |
Trial Result | |||||
 Negative | 37 (52) | 22 (61) | 0.1237 | 10 (53) | 0.9578 |
 Positive | 34 (49) | 14 (39) |  | 9 (47) |  |
Funding Source | |||||
 Non-pharma | 33 (46) | 13 (36) | 0.0757 | 8 (42) | 0.6551 |
 Pharma | 38 (54) | 23 (64) |  | 11 (58) |  |
Duration of Trial | |||||
 < 3 years | 30 (42) | 18 (50) | 0.1802 | 9 (47) | 0.5979 |
 ≥ 3 years | 41 (58) | 18 (50) |  | 10 (53) |  |
Number of protocol non-primary endpointsa | |||||
 ≤ 6 | 36 (51) | 15 (42) | 0.1224 | 9 (47) | 0.7340 |
 > 6 | 35 (49) | 21 (58) |  | 10 (53) |  |
Protocol Lengtha | |||||
 ≤ 34 pages | 36 (51) | 18 (50) | 0.8292 | 8 (42) | 0.0326 |
 > 34 pages | 35 (49) | 18 (50) |  | 11 (58) |  |
Study Phaseb | |||||
 II | 10 (14) | 6 (17) | 0.5993 | 3 (16) | 0.3972 |
 III | 57 (50) | 29 (81) |  | 14 (74) |  |
Study Intervention | |||||
 Systemic | 53 (75) | 30 (83) | 0.0880 | 15 (79) | 0.7624 |
 Non-systemic | 18 (25) | 6 (17) |  | 4 (21) |  |
Protocol Type | |||||
 Full | 60 (85) | 31 (86) | 0.7048 | 18 (95) | 0.2670 |
 Appended | 11 (15) | 5 (14) |  | 1 (5) |  |